Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PELO antisense RNA 1 (PELO-AS1) is a human long noncoding RNA, meaning it is a functional RNA molecule transcribed from DNA but not translated into protein[3][7]. It is affiliated with the class of lncRNAs (long noncoding RNAs), and its locus is listed under several external databases (HGNC: 56263, NCBI Gene: 125775243, Ensembl: ENSG00000248898)[3]. LncRNAs, including antisense RNAs like PELO-AS1, typically modulate gene expression by interacting with regulatory elements, chromatin, and sometimes mRNA itself, impacting transcription, translation, and epigenetic marks[4]. No current evidence supports PELO-AS1 as a therapeutic target, disease-associated RNA, or biomarker, and there are no known drugs that directly interact with or target PELO-AS1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PELO antisense RNA 1 (PELO-AS1).